Incyte (INCY) Restructuring Costs (2016)

Incyte (INCY) reported Restructuring Costs of $1.6 million for Q4 2016, up 6.67% quarter-over-quarter from $1.5 million in Q3 2016.

Incyte (INCY) Restructuring Costs (2016) Analysis & Trends

Incyte has reported Restructuring Costs for 1 years, with the latest figure at $1.6 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Incyte	19.62 Bn	15.60 Bn	1.17 Bn

Download Data